Price Alert

GlycoMimetics Inc. (GLYC)

NASDAQ: GLYC · Real-Time Price · USD

15.71

-0.44 (-2.72%)

At close: Jul 02, 2025, 3:58 PM

-2.72% (1D)

Bid	15.14
Market Cap	1.01B
Revenue (ttm)	54.09K
Net Income (ttm)	-19.39M
EPS (ttm)	-46
PE Ratio (ttm)	-0.34141304347826085
Forward PE	-523.5
Analyst	n/a

Ask	17.4
Volume	612
Avg. Volume (20D)	19,728
Open	16.25
Previous Close	16.15
Day's Range	15.52 - 17.39
52-Week Range	0.15 - 63.00
Beta	1.60

About GLYC

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol GLYC

Website n/a

Full Company Profile

Why Price Moved

2 months ago

-5.43%

GlycoMimetics shares are trading higher after the ... Unlock content with Pro Subscription

9 months ago

+191.32%

GlycoMimetics shares are trading higher after the company announced it will merge with Crescent Biopharma and secured $200 in funding to advance its oncology pipeline.

News

2 months ago · businesswire.com

GlycoMimetics Stockholders Approve Proposed Merger with Crescent Biopharma and All Related Proposals

ROCKVILLE, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (Nasdaq: GLYC) (“GlycoMimetics”) today announced that its stockholders have approved the proposed merger (the “Merger”) with Crescent Biopharma, In...

3 months ago · businesswire.com

GLYCOMIMETICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of GlycoMimetics, Inc. - GLYC

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of GlycoMimetics,...